FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1883249332> ?p ?o ?g. }

• W1883249332 endingPage "1363" @default.
• W1883249332 startingPage "1353" @default.
• W1883249332 abstract "PURPOSE To evaluate prospectively the feasibility and results of bone marrow transplantation (BMT) after induction and intensification chemotherapy (CT) in patients with de novo acute myeloid leukemia (AML). PATIENTS AND METHODS A total of 159 patients less than 51 years of age were treated. Induction CT consisted of daunorubicin 60 mg/m2 for 3 days, cytarabine (ARA-C) 100mg/m2 for 7 days, and etoposide 100 mg/m2 for 3 days. The first intensification therapy included mitoxantrone 10 mg/m2 for 3 days and ARA-C 1.2 g/m2 every 12 hours for 4 days. Amsacrine (100 or 150 mg/m2 for 3 days) and ARA-C (1.2 g/m2 every 12 hours for 2 or 4 days) were given as the second intensification therapy. Depending on the availability of a human leukocyte antigen (HLA)-identical sibling, the intention of treatment after CT was allogeneic BMT (allo-BMT) or autologous BMT (ABMT). RESULTS Complete remission (CR) was obtained in 120 patients (75%) and partial remission (PR) in 11 (7%), while 15 patients (10%) were refractory and 13 (8%) died during induction. There was a trend for better leukemia-free survival (LFS) at 4 years for patients assigned to the ABMT group (50% +/- 6%) compared with the allo-BMT group (31% +/- 7%) (P = .08). This difference in LFS reached statistical significance when considering only transplanted patients (63% +/- 3% at 4 years after ABMT and 38% +/- 11% after allo-BMT, P = .02). The favorable results in patients who received ABMT (no toxic deaths and 37% +/- 7% probability of relapse at 4 years) contrast with the poor outcome of allografted patients (11 patients with transplant-related mortality). CONCLUSION Our study reflects the difficulties in the completion of a therapeutic strategy that include BMT and suggests that intensification before BMT may be useful in the setting of ABMT, but this approach was associated with a high mortality rate in allo-BMT patients." @default.
• W1883249332 created "2016-06-24" @default.
• W1883249332 creator A5000616827 @default.
• W1883249332 creator A5003740257 @default.
• W1883249332 creator A5004861314 @default.
• W1883249332 creator A5006173909 @default.
• W1883249332 creator A5006467382 @default.
• W1883249332 creator A5007682014 @default.
• W1883249332 creator A5008564951 @default.
• W1883249332 creator A5010911026 @default.
• W1883249332 creator A5020155090 @default.
• W1883249332 creator A5025894116 @default.
• W1883249332 creator A5028965719 @default.
• W1883249332 creator A5029260153 @default.
• W1883249332 creator A5031716314 @default.
• W1883249332 creator A5033473574 @default.
• W1883249332 creator A5042038610 @default.
• W1883249332 creator A5051683519 @default.
• W1883249332 creator A5066427858 @default.
• W1883249332 creator A5068240503 @default.
• W1883249332 creator A5068295181 @default.
• W1883249332 creator A5083196574 @default.
• W1883249332 creator A5084354003 @default.
• W1883249332 creator A5086556836 @default.
• W1883249332 creator A5087818948 @default.
• W1883249332 creator A5089188528 @default.
• W1883249332 date "1996-04-01" @default.
• W1883249332 modified "2023-10-17" @default.
• W1883249332 title "Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation." @default.
• W1883249332 cites W151316131 @default.
• W1883249332 cites W159533158 @default.
• W1883249332 cites W1902703187 @default.
• W1883249332 cites W1919339218 @default.
• W1883249332 cites W1975092748 @default.
• W1883249332 cites W2000119898 @default.
• W1883249332 cites W2008682454 @default.
• W1883249332 cites W2013051826 @default.
• W1883249332 cites W2038252730 @default.
• W1883249332 cites W2055079427 @default.
• W1883249332 cites W2067131989 @default.
• W1883249332 cites W2076075328 @default.
• W1883249332 cites W2086586003 @default.
• W1883249332 cites W2142097265 @default.
• W1883249332 cites W2147213204 @default.
• W1883249332 cites W2150113701 @default.
• W1883249332 cites W2151367307 @default.
• W1883249332 cites W2318674152 @default.
• W1883249332 cites W2337137217 @default.
• W1883249332 cites W2398929488 @default.
• W1883249332 cites W2400199124 @default.
• W1883249332 cites W2411121819 @default.
• W1883249332 cites W2412475735 @default.
• W1883249332 cites W2413746212 @default.
• W1883249332 cites W2416325941 @default.
• W1883249332 cites W2416756744 @default.
• W1883249332 cites W2417246488 @default.
• W1883249332 cites W2441778018 @default.
• W1883249332 cites W2468642970 @default.
• W1883249332 cites W2508730074 @default.
• W1883249332 cites W3041047318 @default.
• W1883249332 cites W368475356 @default.
• W1883249332 cites W37410012 @default.
• W1883249332 cites W63132846 @default.
• W1883249332 cites W79968274 @default.
• W1883249332 doi "https://doi.org/10.1200/jco.1996.14.4.1353" @default.
• W1883249332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8648394" @default.
• W1883249332 hasPublicationYear "1996" @default.
• W1883249332 type Work @default.
• W1883249332 sameAs 1883249332 @default.
• W1883249332 citedByCount "42" @default.
• W1883249332 countsByYear W18832493322013 @default.
• W1883249332 countsByYear W18832493322015 @default.
• W1883249332 countsByYear W18832493322018 @default.
• W1883249332 crossrefType "journal-article" @default.
• W1883249332 hasAuthorship W1883249332A5000616827 @default.
• W1883249332 hasAuthorship W1883249332A5003740257 @default.
• W1883249332 hasAuthorship W1883249332A5004861314 @default.
• W1883249332 hasAuthorship W1883249332A5006173909 @default.
• W1883249332 hasAuthorship W1883249332A5006467382 @default.
• W1883249332 hasAuthorship W1883249332A5007682014 @default.
• W1883249332 hasAuthorship W1883249332A5008564951 @default.
• W1883249332 hasAuthorship W1883249332A5010911026 @default.
• W1883249332 hasAuthorship W1883249332A5020155090 @default.
• W1883249332 hasAuthorship W1883249332A5025894116 @default.
• W1883249332 hasAuthorship W1883249332A5028965719 @default.
• W1883249332 hasAuthorship W1883249332A5029260153 @default.
• W1883249332 hasAuthorship W1883249332A5031716314 @default.
• W1883249332 hasAuthorship W1883249332A5033473574 @default.
• W1883249332 hasAuthorship W1883249332A5042038610 @default.
• W1883249332 hasAuthorship W1883249332A5051683519 @default.
• W1883249332 hasAuthorship W1883249332A5066427858 @default.
• W1883249332 hasAuthorship W1883249332A5068240503 @default.
• W1883249332 hasAuthorship W1883249332A5068295181 @default.
• W1883249332 hasAuthorship W1883249332A5083196574 @default.
• W1883249332 hasAuthorship W1883249332A5084354003 @default.
• W1883249332 hasAuthorship W1883249332A5086556836 @default.
• W1883249332 hasAuthorship W1883249332A5087818948 @default.
• W1883249332 hasAuthorship W1883249332A5089188528 @default.

• next